NO20064908L - Konbinasjonsdoseringskur for erytropoietin - Google Patents

Konbinasjonsdoseringskur for erytropoietin

Info

Publication number
NO20064908L
NO20064908L NO20064908A NO20064908A NO20064908L NO 20064908 L NO20064908 L NO 20064908L NO 20064908 A NO20064908 A NO 20064908A NO 20064908 A NO20064908 A NO 20064908A NO 20064908 L NO20064908 L NO 20064908L
Authority
NO
Norway
Prior art keywords
dosing regimen
erythropoietin
dosing
epo
combination dosing
Prior art date
Application number
NO20064908A
Other languages
English (en)
Inventor
Wing K Cheung
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20064908L publication Critical patent/NO20064908L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det tilveiebringes et kombinasjonsdoseringsregime for erytropoietin (EPO). Mer spesielt inkluderer de foreliggende doseringsregimer administrering av minst et første doseringsseginent omfattende en første eksponering til EPO i stand til 'a stimulere produksjonen av retikulocytter fulgt av en andre eksponering til EPO som er i stand til åbibeholde maturering av retikulocyttene til neocytter, og deretter til slutt til røde blodlegemer. Fordelaktig kan doseringssegmentet sykliseres eller gjentas et hvilket som helst antall ganger og i henhold til et hvilket som helst ønsket tidsskjema for å gi eller opprettholde enhver ønsket telling av totale røde blodlegemer og/eller hemoglobinkonsentrasjonen. Metoder for behandling benytter kombinasjonsdoseringsregimet, og det tilveiebringes også sett for gjennomføring derav.
NO20064908A 2004-03-26 2006-10-26 Konbinasjonsdoseringskur for erytropoietin NO20064908L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55692304P 2004-03-26 2004-03-26
PCT/US2005/009873 WO2005097167A1 (en) 2004-03-26 2005-03-24 Combination dosing regimen for erythropoietin

Publications (1)

Publication Number Publication Date
NO20064908L true NO20064908L (no) 2006-12-15

Family

ID=34964370

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064908A NO20064908L (no) 2004-03-26 2006-10-26 Konbinasjonsdoseringskur for erytropoietin

Country Status (17)

Country Link
US (1) US20050267026A1 (no)
EP (1) EP1737484A1 (no)
JP (1) JP2007530578A (no)
KR (1) KR20070015549A (no)
CN (1) CN1960745A (no)
AU (1) AU2005231307A1 (no)
BR (1) BRPI0509239A (no)
CA (1) CA2561222A1 (no)
CR (1) CR8705A (no)
EA (1) EA010889B1 (no)
EC (1) ECSP066885A (no)
IL (1) IL178288A0 (no)
MX (1) MXPA06011084A (no)
NO (1) NO20064908L (no)
UA (1) UA89630C2 (no)
WO (1) WO2005097167A1 (no)
ZA (1) ZA200608877B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164991A1 (en) * 2013-11-01 2015-06-18 Vanderbilt University Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1367701A (zh) * 1999-05-11 2002-09-04 奥索－麦克尼尔药物公司 红细胞生成素给药的药代动力学和药效模型
NZ516735A (en) * 1999-07-22 2004-01-30 Aventis Pharma Inc Multi-dose erythropoietin formulations containing benzethonium chloride as a preservative
DK1311285T4 (en) * 2000-05-15 2017-07-24 Hoffmann La Roche Liquid pharmaceutical composition containing an erythropoietin derivative
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects

Also Published As

Publication number Publication date
WO2005097167A1 (en) 2005-10-20
ZA200608877B (en) 2008-06-25
EP1737484A1 (en) 2007-01-03
IL178288A0 (en) 2006-12-31
CR8705A (es) 2008-09-09
AU2005231307A1 (en) 2005-10-20
MXPA06011084A (es) 2007-03-21
CA2561222A1 (en) 2005-10-20
ECSP066885A (es) 2006-11-24
EA010889B1 (ru) 2008-12-30
KR20070015549A (ko) 2007-02-05
US20050267026A1 (en) 2005-12-01
BRPI0509239A (pt) 2007-09-04
CN1960745A (zh) 2007-05-09
EA200601782A1 (ru) 2007-04-27
JP2007530578A (ja) 2007-11-01
UA89630C2 (ru) 2010-02-25

Similar Documents

Publication Publication Date Title
ES2164841T3 (es) Derivados de benzoimidazol, su preparacion y sus usos terapeuticos.
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NZ596420A (en) Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
WO2006050330A3 (en) Platelets from stem cells
Malheiro et al. CO2 availability rather than light and temperature determines growth and phenotypical responses in submerged Myriophyllum aquaticum
WO2009079910A8 (zh) 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
EA201001287A1 (ru) Лечение гиперглицемии 25-гидроксивитамином d3
WO2007136641A3 (en) Methods of treating acute blood loss anemia with a cross-linked hemoglobin blood substitute
NO20064908L (no) Konbinasjonsdoseringskur for erytropoietin
WO2023150493A3 (en) Cell therapy for diabetes
CN104745479B (zh) 一种培养雨生红球藻的方法
NO20060561L (no) Peparater inneholdende sertoliceller og myoidceller og anvendelse av disse i celletransplantater
WO2004094610A3 (en) Wnt as a factor for cardiac myogenesis
NO20062360L (no) Et universelt anvendelig virus-inaktivert blodplasma fremstilt fra deler av ikke-kaukasisk plasma
BR0316822A (pt) Recombinação de dna especìfica da sequência em células eucarióticas
Howlett A civic slant on child training in the preschool years
NO20064814L (no) Fremgangsmate for forebygging av nodavirusinfeksjon og terapeutisk fremgangsmate
Uchida et al. Development of a clinically applicable method for high-efficiency gene correction of plerixafor-mobilized CD34+ cells from patients with sickle cell disease
Sindhva et al. Naadi Chakra
CN104403868A (zh) 一种保健酒及其制备方法
RU2004136437A (ru) Способ лечения начальных форм цереброваскулярной патологии на фоне артериальной гипертонии
Huber Effects of catechol-o-methyltransferase on reinforcement learning and mesolimbic dopamine transmission
Izpisua-Belmonte Turning Back the Aging Clock
RU2000118076A (ru) Способ лечения ишемической болезни сердца, стенокардии напряжения I-II функциональных классов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application